Histology
Non-Small Cell Adenocarcinoma
CI-CAN-00003439Explore in graph →
53 active trials127 evidence items
- NCIt
- C27745
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00003439Explore in graph →
Clinical trials
236 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (29)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05675033 | Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma | unknown | Phase 2 | 50 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 9, 2023 | clinicaltrials |
| NCT04459078 | Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma | unknown | Phase 2 | 63 | Hunan Cancer HospitalOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT05079022 |
| ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas |
| unknown |
| Phase 1 / Phase 2 |
| 50 |
| Peking University People's HospitalOTHER |
| 1 |
| Oct 15, 2021 |
| clinicaltrials |
| NCT04965831 | Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 16, 2021 | clinicaltrials |
| NCT03298763 | Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer(TACTICAL) | unknown | Phase 1 / Phase 2 | 46 | University College, LondonOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT03254004 | Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm | unknown | Phase 2 | 70 | Samsung Medical CenterOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT02737774 | Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation | unknown | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 1, 2020 | clinicaltrials |
| NCT03905317 | Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene | unknown | Phase 2 | 66 | Sun Yat-sen UniversityOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT03486496 | Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation(Geber) | unknown | Phase 2 | 50 | Fujian Cancer HospitalOTHER_GOV | 1 | Apr 3, 2018 | clinicaltrials |
| NCT03376737 | Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma | unknown | Phase 2 | 120 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 18, 2017 | clinicaltrials |
| NCT02787447 | Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy | unknown | Phase 2 | 46 | First People's Hospital of HangzhouOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT02951637 | Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial | unknown | Phase 2 | 300 | Shanghai Chest HospitalOTHER | 0 | Nov 1, 2016 | clinicaltrials |
| NCT02788058 | A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy | unknown | Phase 2 | 76 | First People's Hospital of HangzhouOTHER | 0 | Jun 2, 2016 | clinicaltrials |
| NCT00339586 | First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene | unknown | Phase 2 | 40 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 21, 2006 | clinicaltrials |
Data updated 23 days agoSource updated Jan 9, 2023source: clinicaltrials